Scarica l'app Stockscreener
6.83
2.57%
-0.18
Dopo l'orario di chiusura:
6.80
-0.03
-0.44%
Precedente Chiudi:
$7.01
Aprire:
$7.05
Volume 24 ore:
382.72K
Relative Volume:
0.75
Capitalizzazione di mercato:
$146.79M
Reddito:
$675.00K
Utile/perdita netta:
$-33.47M
Rapporto P/E:
-2.4412
EPS:
-2.7978
Flusso di cassa netto:
$-29.88M
1 W Prestazione:
+3.64%
1M Prestazione:
+10.16%
6M Prestazione:
+76.49%
1 anno Prestazione:
+1,073%
Intervallo 1D:
$6.775
$7.14
Intervallo di 1 settimana:
$6.50
$7.20
Portata 52W:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Nome
Unicycive Therapeutics Inc
Settore
Industria
Telefono
650-384-0642
Indirizzo
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.83 | 146.79M | 675.00K | -33.47M | -29.88M | -2.7978 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | Guggenheim | Buy |
| 2024-04-04 | Iniziato | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Integer - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Boston - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Aug Setups: Is Unicycive Therapeutics Inc on track to beat earningsTrade Volume Report & Fast Gain Stock Tips - baoquankhu1.vn
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm - TMX Newsfile
Important Notice to Long-Term Shareholders of Corcept - GlobeNewswire
UNCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
UNCY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Unicycive's OLC Address Hyperphosphatemia's Unmet Need With Its 3P Advantage? - RTTNews
Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Unicycive Therapeutics Inc. benefit from current market trendsJuly 2025 Snapshot & Verified Entry Point Signals - mfd.ru
Why is Unicycive Therapeutics Inc. stock going downJuly 2025 Spike Watch & Comprehensive Market Scan Insights - mfd.ru
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2026-02-19 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4%Should You Buy? - MarketBeat
2026-02-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Will Unicycive Therapeutics Inc. stock go up in YEAR2025 Trade Ideas & Safe Entry Zone Tips - mfd.ru
UNCY Should I Buy - Intellectia AI
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Octagon discloses 1M Unicycive (UNCY) shares, holding under 5% - Stock Titan
Unicycive Therapeutics: Speculative Biotech Stock Whipsaws Traders As Wall Street Stays Cautious - AD HOC NEWS
Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech Summit - The Manila Times
Biotech CEO Shalabh Gupta set for Guggenheim fireside chat Feb. 11 - Stock Titan
Unicycive Therapeutics Doubles Stock Sale Agreement - MSN
Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX) and Unicycive Therapeutics (UNCY) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile - Seeking Alpha
Take two: Company tries again to win FDA approval for drug for dialysis patients - The Business Journals
Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate (OLC) new drug application (NDA) resubmission - marketscreener.com
UPDATEUnicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance Of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - TradingView
Unicycive granted FDA review for resubmitted marketing application for kidney disease drug - Seeking Alpha
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission - The Manila Times
Unicycive Therapeutics Announces FDA Acceptance of - GlobeNewswire
FY2030 Earnings Forecast for UNCY Issued By HC Wainwright - Defense World
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
2026-01-27 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Analysts Set Expectations for UNCY FY2030 Earnings - MarketBeat
Trading Action: Will Unicycive Therapeutics Inc benefit from current market trends2025 Growth vs Value & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
2026-01-20 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - accessnewswire.com
Unicycive Therapeutics Inc Azioni (UNCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):